Stock analysts at Leerink Partnrs reduced their FY2024 EPS estimates for shares of United Therapeutics in a research note issued on Tuesday, February 11th. Leerink Partnrs analyst R. Ruiz now expects ...

Oppenheimer analyst Jason Helfstein maintained a Buy rating on Trade Desk (TTD – Research Report) yesterday and set a price target of $115.00.

Tesla (NASDAQ:TSLA) shares rose 2.5% today, but the stock remains down ~17% year-to-date, suggesting the post-election ...

Amgen, Inc. ( NASDAQ: AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - ...

Johnny Depp as Captain Jack Sparrow? Robert Downey Jr. in "Tropic Thunder"? You'd be shocked by the roles that have received ...

OpenAI was cofounded by Musk and Altman in 2018 as a non-profit, with Musk leaving before the company took off. Musk’s ...

Tesla (TSLA) is advancing 3% after investment bank Benchmark started coverage of the automaker with a Buy rating.

Analysts at Oppenheimer said in a research note on Tuesday that billionaire Elon Musk's recent bid for ChatGPT parent OpenAI ...

At its current premarket price, Tesla's stock is down 33% since hitting a record high on Dec. 18, 2024, weeks after the ...

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “market perform” rating restated by analysts at Oppenheimer in a research note issued to investors on Monday, MarketBeat.com reports ...

Oqory, Inc., a private biopharmaceutical company dedicated to developing next-generation antibody drug conjugates (ADCs) for the treatment of cancer, today announced that Michael King, Chief Executive ...

BYD had previously offered self-driving technology to cars costing $30,000 and higher, but analysts noted that will now be offered on 21 models, including some under $10,000. Tesla's full self-driving ...